For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

OpenAI CEO Sam Altman and Meta both announced $1 million donations, and Amazon and Apple CEO Tim Cook have also reportedly ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

South Korea’s government continued to ramp up investment in its pharmaceutical and med-tech sector in 2025, including a 7.2% ...

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...